Mirae Asset Global Investments Co. Ltd. Acquires 6,383 Shares of Insmed Incorporated (NASDAQ:INSM)

Mirae Asset Global Investments Co. Ltd. raised its position in Insmed Incorporated (NASDAQ:INSM) by 9.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,904 shares of the biopharmaceutical company’s stock after acquiring an additional 6,383 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Insmed were worth $2,383,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new position in Insmed in the 4th quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. raised its holdings in Insmed by 347.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,551 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 12,853 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Insmed by 8.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 284,520 shares of the biopharmaceutical company’s stock worth $8,817,000 after buying an additional 22,384 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Insmed by 5.0% in the 4th quarter. Diversified Trust Co now owns 20,606 shares of the biopharmaceutical company’s stock worth $639,000 after buying an additional 972 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Insmed by 7.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,345,512 shares of the biopharmaceutical company’s stock worth $362,224,000 after buying an additional 1,024,956 shares in the last quarter.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent research reports. Wolfe Research initiated coverage on Insmed in a report on Thursday, February 15th. They issued an “outperform” rating and a $42.00 target price for the company. UBS Group initiated coverage on Insmed in a report on Tuesday, February 27th. They issued a “buy” rating and a $46.00 target price for the company. Guggenheim increased their target price on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. StockNews.com raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Barclays increased their target price on Insmed from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.64.

Insmed Stock Performance

Shares of INSM opened at $24.80 on Friday. The business’s fifty day moving average price is $27.53 and its two-hundred day moving average price is $27.03. The firm has a market capitalization of $3.68 billion, a price-to-earnings ratio of -4.64 and a beta of 0.92. Insmed Incorporated has a 52 week low of $17.41 and a 52 week high of $32.00.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The firm had revenue of $83.70 million during the quarter, compared to the consensus estimate of $82.15 million. The business’s revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.20) earnings per share. As a group, research analysts forecast that Insmed Incorporated will post -4.65 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.